Opticeutical Inc.
Built on Science.
The Company
Opticeutical Inc. is a product family of Atumnus Longevity Platform Company. Co-founded by Daniel Nowak (CTO) and Daniel William Dorsey (CEO). Incorporated with a mission to bring published bioregulator peptide science to consumers without a prescription barrier.
The Patents
Proprietary bioregulator formulations protected across eight IP domains. Patent Pending.
The Manufacturing
Manufactured by Activation Products, Canada — an established cGMP facility with 19 years of operation and $22M CAD in manufacturing assets, currently operating at approximately 7% capacity. Partnership under active negotiation.
The Research Foundation
All formulas are built on published peer-reviewed research. Primary references include PMC12411320 (hTERT upregulation, Brunel University London 2025) and PMC3016279 (GHK-Cu transdermal permeability). Over 800 publications from the Khavinson Institute underpin the bioregulator science.